Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Operating Leases (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Operating Leases data on record, last reported at $5.0 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 2.86% year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, down 2.86%, while the annual FY2024 figure was $463000.0, 76.62% down from the prior year.
  • Operating Leases reached $5.0 million in Q3 2025 per AMLX's latest filing, down from $5.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.8 million in Q1 2022 and bottomed at $327000.0 in Q1 2025.
  • Average Operating Leases over 4 years is $3.0 million, with a median of $2.9 million recorded in 2023.
  • Peak YoY movement for Operating Leases: tumbled 76.62% in 2024, then soared 586.14% in 2025.
  • A 4-year view of Operating Leases shows it stood at $4.2 million in 2022, then crashed by 53.27% to $2.0 million in 2023, then tumbled by 76.62% to $463000.0 in 2024, then soared by 969.98% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $5.0 million in Q3 2025, $5.3 million in Q2 2025, and $327000.0 in Q1 2025.